Financial
Teva looking at up to $25 billion in bond sale to fund Allergan’s generic-unit buy – reports
July 15, 2016Medical Communications, Sales and Marketing Allergan, Financial, Teva, US regulators, bond sale, deal
Israeli drug firm Teva (NYSE: TEVA) is looking at a $20 billion to $25 billion bond sale in the US …
Sanofi signs confidentiality agreement with Medivation for due diligence access for potential deal
July 6, 2016Research and Development, Sales and Marketing Financial, M&A, MA, Medivation, Sanofi, deal, offer
Sanofi (Euronext: SAN) confirmed it has entered a confidentiality agreement with cancer drugmaker Medivation (Nasdaq: MDVN) under which it will …
Sanofi, Boehringer Ingelheim sign definitive agreements for swap
June 27, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, Financial, Sanofi, business swap, merger and acquisition
French drugmaker Sanofi (Euronext: SAN) and German pharma firm Boehringer Ingelheim have signed a definitive agreement for a business swap announced …
Merck & Co agrees to buy biotech firm Afferent for upfront $500 million in cash
June 10, 2016Medical Communications, Sales and Marketing Afferent Pharmaceuticals, Financial, M&A, MA, Merck & Co
US drugmaker Merck & Co (NYSE: MRK) said it has agreed to buy biotech firm Afferent Pharmaceuticals for an upfront …
Monsanto rejects Bayer’s $62 billion offer
May 25, 2016Business Services, Research and Development, Sales and Marketing Bayer, Financial, M&A, MA, deal, monsanto
World’s largest seed maker Monsanto (NYSE: MON) has rejected the $62 billion takeover offer from Germany’s Bayer AG (ETR: BAYN) …
Weekly Movers: Valeant, Anacor, Regeneron…
May 23, 2016Manufacturing and Production, Research and Development, Sales and Marketing Acorda, Aduro Biotech, Anacor Pharma, Financial, MacroGenics, Merck, Regeneron Pharma, Valeant Pharma
The earnings season came to a close with Germany’s Merck doubling its first-quarter profits. For the week, drug trials, analyst …
Bayer offers $62 billion for Monsanto in all cash deal
May 23, 2016Research and Development, Sales and Marketing Bayer, Deals, Financial, Merger & Acquisition, monsanto
German pharma and crop sciences giant Bayer (ETR: BAYN) has made an unsolicited $62 billion all-cash offer for Monsanto Co …
Germany’s Merck Q1 profits double boosted by Sigma-Aldrich deal
May 19, 2016Business Services, Sales and Marketing Financial, Merck, Q1, Sigma-Aldrich, deal, earnings, results
Germany’s Merck on Thursday said first-quarter net profit more than doubled helped by the integration of US laboratory equipment maker …
Allergan to buy back $10 billion of stock, Q1 earnings rise
May 11, 2016Research and Development, Sales and Marketing Allergan, Buy Back, Financial, Q1, earnings, results, revenue
Botox-maker Allergan (NYSE: AGN) said it plans to buy back as much as $10 billion in stock after completing the …
Merck & Co Q1 sales hurt by generics, currency impact
May 6, 2016Medical Communications, Sales and Marketing Financial, Merck & Co, Q1, Revenye, earnings, results, sales
US pharma major Merck & Co (NYSE: MRK) posted a drop in first-quarter sales impacted the launch of generic competition …
Mylan Q1 revenue up 17%, maintains FY view
May 3, 2016Manufacturing and Production, Sales and Marketing Financial, Mylan, Q1, results, revenue, sales
Pharma firm Mylan NV (Nasdaq: MYL) on Tuesday reported a 17% rise in first-quarter revenue and said it maintains its …
Novo Nordisk Q1 operating profit down 10% in local currencies
April 29, 2016Medical Communications, Sales and Marketing Financial, Novo Nordisk, Q1, earnings, outlook, results
Denmark’s Novo Nordisk (NYSE: NOV) on Friday posted a 10% drop in first-quarter operating profit and said it maintains its full year …
Novartis exploring almost $14-billion stake sale in Roche – reports
April 26, 2016Manufacturing and Production, Sales and Marketing Financial, Merger & Acquisition, Novartis, Roche, Stake sale
Swiss pharma firm Novartis (VTX: NOVN) maybe looking at options to sell its one-third stake in cancer drugmaker Roche’s (VTX: …
Novartis Q1 earnings drop as cancer drug sales falter
April 21, 2016Business Services, Sales and Marketing Financial, Novartis, earnings, first quarter, results
Swiss drugmaker Novartis (SIX: NOVN) on Thursday reported a 13% drop in net income for the first quarter on the …
Latest content
